Pharmacoeconomics, Epidemiology, Pharmaceutical Policy, and Outcomes Research program, Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA.
Ann Pharmacother. 2013 Mar;47(3):380-7. doi: 10.1345/aph.1R417. Epub 2013 Mar 5.
To review the use of number needed to treat (NNT) and/or number needed to harm (NNH) values to determine their relevance in helping clinicians evaluate cost-effectiveness analyses (CEAs).
PubMed and EconLit were searched from 1966 to September 2012.
Reviews, editorials, non-English-language articles, and articles that did not report NNT/NNH or cost-effectiveness ratios were excluded. CEA studies reporting cost per life-year gained, per quality-adjusted life-year (QALY), or other cost per effectiveness measure were included. Full texts of all included articles were reviewed for study information, including type of journal, impact factor of the journal, focus of study, data source, publication year, how NNT/NNH values were reported, and outcome measures.
A total of 188 studies were initially identified, with 69 meeting our inclusion criteria. Most were published in clinician-practice-focused journals (78.3%) while 5.8% were in policy-focused journals, and 15.9% in health-economics-focused journals. The majority (72.4%) of the articles were published in high-impact journals (impact factor >3.0). Many articles focused on either disease treatment (40.5%) or disease prevention (40.5%). Forty-eight percent reported NNT as a part of the CEA ratio per event. Most (53.6%) articles used data from literature reviews, while 24.6% used data from randomized clinical trials, and 20.3% used data from observational studies. In addition, 10% of the studies implemented modeling to perform CEA.
CEA studies sometimes include NNT ratios. Although it has several limitations, clinicians often use NNT for decision-making, so including NNT information alongside CEA findings may help clinicians better understand and apply CEA results. Further research is needed to assess how NNT/NNH might meaningfully be incorporated into CEA publications.
回顾治疗需要人数(NNT)和/或需要治疗人数(NNH)值的使用情况,以确定其在帮助临床医生评估成本效益分析(CEA)方面的相关性。
从 1966 年至 2012 年 9 月,在 PubMed 和 EconLit 上进行了检索。
排除了 NNT/NNH 或成本效益比报告的综述、社论、非英语文章和未报告 NNT/NNH 或成本效益比的文章。纳入了报告每获得一个生命年的成本、每获得一个质量调整生命年(QALY)的成本或其他每有效措施的成本的 CEA 研究。所有纳入文章的全文均进行了研究信息的综述,包括期刊类型、期刊影响因子、研究重点、数据来源、出版年份、NNT/NNH 值的报告方式和结局指标。
最初确定了 188 项研究,其中 69 项符合我们的纳入标准。大多数发表在以临床医生为重点的期刊上(78.3%),5.8%发表在以政策为重点的期刊上,15.9%发表在以健康经济学为重点的期刊上。大多数(72.4%)文章发表在高影响因子的期刊上(影响因子>3.0)。许多文章集中于疾病治疗(40.5%)或疾病预防(40.5%)。48%的文章报告了 NNT 作为每事件 CEA 比值的一部分。大多数(53.6%)文章使用文献综述的数据,24.6%使用随机临床试验的数据,20.3%使用观察性研究的数据。此外,10%的研究实施了建模来进行 CEA。
CEA 研究有时包括 NNT 比值。尽管 NNT 有几个局限性,但临床医生通常将 NNT 用于决策,因此在 CEA 结果中包含 NNT 信息可能有助于临床医生更好地理解和应用 CEA 结果。需要进一步研究如何有意义地将 NNT/NNH 纳入 CEA 出版物。